- Home
- TGTX vs SLM Comparison
TGTX vs SLM Comparison
Compare TGTX & SLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- SLM
- Stock Information
- Founded
- TGTX 1993
- SLM 1972
- Country
- TGTX United States
- SLM United States
- Employees
- TGTX N/A
- SLM N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- SLM Finance: Consumer Services
- Sector
- TGTX Health Care
- SLM Finance
- Exchange
- TGTX Nasdaq
- SLM Nasdaq
- Market Cap
- TGTX 5.4B
- SLM 4.6B
- IPO Year
- TGTX 1995
- SLM N/A
- Fundamental
- Price
- TGTX $32.91
- SLM $27.68
- Analyst Decision
- TGTX Strong Buy
- SLM Buy
- Analyst Count
- TGTX 6
- SLM 10
- Target Price
- TGTX $40.67
- SLM $25.70
- AVG Volume (30 Days)
- TGTX 2.3M
- SLM 2.6M
- Earning Date
- TGTX 11-04-2024
- SLM 01-22-2025
- Dividend Yield
- TGTX N/A
- SLM 1.89%
- EPS Growth
- TGTX N/A
- SLM 117.36
- EPS
- TGTX N/A
- SLM 2.91
- Revenue
- TGTX $264,790,000.00
- SLM $1,586,141,000.00
- Revenue This Year
- TGTX $43.74
- SLM N/A
- Revenue Next Year
- TGTX $64.30
- SLM $7.55
- P/E Ratio
- TGTX N/A
- SLM $9.50
- Revenue Growth
- TGTX 39.53
- SLM 46.87
- 52 Week Low
- TGTX $12.84
- SLM $18.04
- 52 Week High
- TGTX $36.84
- SLM $28.22
- Technical
- Relative Strength Index (RSI)
- TGTX 55.20
- SLM 66.78
- Support Level
- TGTX $30.41
- SLM $26.91
- Resistance Level
- TGTX $35.03
- SLM $28.01
- Average True Range (ATR)
- TGTX 1.55
- SLM 0.63
- MACD
- TGTX -0.33
- SLM 0.00
- Stochastic Oscillator
- TGTX 51.78
- SLM 91.47
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
About SLM SLM Corporation
SLM Corp is the largest student lender in the country. It makes and holds student loans through the guaranteed Federal Family Education Loan Program as well as through private channels. It also engages in debt-management operations, including accounts receivable and collections services, and runs college savings programs.